Menu

Frequently asked Questions

General FAQs

NorthernBio works with many species that are considered most appropriate for the model or therapeutic being developed. We work with rodents (rats and mice), rabbits, dogs, pigs, sheep, and nonhuman primates.

NorthernBio is committed to the highest standards of animal care.  As a CRO, we recognize the ethical responsibility to ensure the animals involved in our scientific studies receive the highest level of care. Our highly trained and dedicated veterinary and operational teams work diligently, not only providing the best forms of enrichment to the animals that we work with, but also ensuring ethical study design. Our protocols are designed to prioritize animal well-being and implementation of the 3Rs principle – Replacement, Reduction, and Refinement.

Neuroscience FAQs

NorthernBio specializes in the targeted delivery of therapeutics to the CNS. Our experts utilize the most advanced surgical techniques to deliver via intracerebroventricular (ICV), intraparenchymal, intracisternal (ICM), intrathecal lumbar, epidural, perineural, etc.

Ophthalmology FAQs

Ocular routes of administration offer a unique challenge in ensuring that the therapeutic reaches the targeted regions of the eye. NorthernBio offers unique capabilities of dosing intracorneal, intravitreal, periocular, intracameral, suprachoroidal, subretinal, etc., to ensure that the therapies that we work with reach the intended targets to maximize efficacy assessment.

Cardiovascular FAQs

NorthernBio supports all of the most common species of animals when assessing cardiovascular therapies. While not limited to, the most common species utilized for these studies are rodents, canines, swine, and nonhuman primates.

Rare Disease Research FAQs

The World Health Organization defines a rare disease as one that strikes fewer than 65 per 100,000 people.

There is a wide range of therapeutics being developed for rare diseases. These include but are not limited to Antisense oligonucleotides (ASOs), Adeno-associated viral vectors (AAVs), enzyme replacement therapies, small molecules, Small interfering RNA (siRNA), and CRISPR Gene editing.

The types of animal studies required are based upon the type of therapeutic being developed.  For most therapeutics, regulatory agencies require studies to be conducted in two species that include a rodent and non-rodent species. 

Bioanalytical Services FAQs

NorthernBio routinely develops customized assays for molecular biology (qPCR, RT-PCR, dPCR, Stem-loop RT-qPCR) and immunogenicity (ADA, Nf-L, cytokine, complement, etc.).

NorthernBio operates on the most advanced technologies for bioanalytical support. For our molecular biology assays, NorthernBio has been equipped with QuantStudio 7, QIAcuity, QIASymphony, and Nanodrop Spectrophotometer platforms. Immunoassay development and analysis, NorthernBio works on Meso Sector 600MM, Spectramax iD5, and Luminex systems.

Partner With Us

Let’s work together to develop
life-changing treatments.

Join us in the pursuit of better lives through scientific innovation. Explore how NorthernBio can help you achieve your research goals.

CONSULT A SCIENTIST